Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alacrita and Debiopharm Group™ Collaborate

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Collaboration to identify early stage drug candidates from the Massachusetts life science cluster.

Alacrita and Debiopharm Group™ (Debiopharm) have established an alliance to identify oncological, autoimmune, infectious diseases as well as metabolic in-licensing opportunities stemming from the Massachusetts life science cluster.

Alacrita will strengthen Debiopharm’s in-house scouting team in their search for small molecules, antibody or peptide-based product candidates.

The companies are seeking preclinical assets against novel targets which represent first-in-class opportunities.

Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company recently in-licensed assets from two Massachusetts companies, including Mercury Therapeutics Inc. (Woburn, MA) and Curis Inc. (Lexington, MA).

In recognition of the depth and breadth of life science innovation in Massachusetts, Debiopharm sees the value of a local presence in the region and has selected Alacrita as its representative.

Alacrita is also in charge of identifying opportunities for Debiopharm elsewhere on the East Coast.

David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: “Massachusetts hosts global leaders in pharmaceutical innovation. As such, the area represents a strategic priority for us as we source opportunities from around the world to expand our pipeline of novel medicines. We are delighted to be working with Alacrita, a leading pharma consultancy on both sides of the Atlantic.”

Rob Johnson, Partner at Alacrita Consulting, said: “Debiopharm’s resources and expertise in global pharmaceutical development make it an ideal partner for Massachusetts organizations looking to move their preclinical programs into clinical trials. Debiopharm has a track record of shepherding early stage pharmaceutical programs into late stage clinical trials and has demonstrated extraordinary success in delivering new medical breakthroughs to patients, a testament to its impressive preclinical, clinical, manufacturing, drug delivery, formulation and regulatory expertise. Alacrita is proud to have been selected by Debiopharm to source new in-licensing opportunities for the group and enable the next generation of medical products.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alacrita Aggregates the Life Science Practices of Two Consulting Firms
Company appoints Simon Turner PhD FRSC as Partner.
Friday, May 10, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!